News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2024 ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH Caitlin E. Cox November 18, 2024
News Conference News AHA 2024 US Obesity Epidemic Continues to Skyrocket, With No End in Sight Michael O'Riordan November 15, 2024
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Conference News AHA 2023 Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing Shelley Wood November 14, 2023
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Conference News AHA 2023 POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy L.A. McKeown November 13, 2023
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Conference News AHA 2023 Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients Caitlin E. Cox November 07, 2023
News Conference News AHA 2022 Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION Michael O'Riordan November 09, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021